We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Novacyt S.a. | LSE:NCYT | London | Ordinary Share | FR0010397232 | EUR1/15TH (CDI) |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 56.40 | 6,774 | 11:24:40 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 55.40 | 57.00 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| In Vitro,in Vivo Diagnostics | 11.58M | -28.29M | - | - | 39.83M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 10:54:29 | O | 154 | 55.56 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 10/12/2024 | 07:00 | UK RNS | Novacyt S.A. Change of Registered Office |
| 02/12/2024 | 16:00 | UK RNS | Novacyt S.A. Liquidity Agreement and Total Voting Rights |
| 14/11/2024 | 13:20 | UK RNS | Novacyt S.A. Further expansion of cost reduction programme |
| 14/11/2024 | 07:00 | UK RNS | Novacyt S.A. London Vet Show: Launch of animal multiplex assays |
| 01/11/2024 | 12:45 | UK RNS | Novacyt S.A. Liquidity Agreement and Total Voting Rights |
| 31/10/2024 | 07:00 | UK RNS | Novacyt S.A. Directorate Change |
| 17/10/2024 | 06:00 | UK RNS | Novacyt S.A. IVDR accreditation |
| 08/10/2024 | 11:30 | UK RNS | Novacyt S.A. Closure of IT-IS International |
| 01/10/2024 | 11:30 | UK RNS | Novacyt S.A. Liquidity Agreement and Total Voting Rights |
| 26/9/2024 | 06:01 | UK RNS | Novacyt S.A. Interim Results |
Novacyt (NCYT) Share Charts1 Year Novacyt Chart |
|
1 Month Novacyt Chart |
Intraday Novacyt Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 12/12/2024 | 20:49 | COVID-19 | 70,567 |
| 13/10/2024 | 13:09 | coronavirusTransmission facts vs fiction | 514 |
| 18/9/2024 | 14:49 | COVID-19..downgraded no longer high consequence infectious disease | 60 |
| 07/10/2023 | 11:26 | NCYT million's | 125 |
| 29/7/2023 | 22:42 | black cloud | 139 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 10:54:30 | 55.56 | 154 | 85.56 | O |
| 08:48:22 | 55.26 | 5,000 | 2,762.93 | O |
| 08:45:14 | 55.40 | 28 | 15.51 | O |
| 08:26:53 | 55.83 | 358 | 199.88 | O |
| 08:17:48 | 55.72 | 1,234 | 687.58 | O |
| Top Posts |
|---|
Posted at 13/12/2024 08:20 by Novacyt Daily Update Novacyt S.a. is listed in the In Vitro,in Vivo Diagnostics sector of the London Stock Exchange with ticker NCYT. The last closing price for Novacyt was 56.40p.Novacyt currently has 70,626,248 shares in issue. The market capitalisation of Novacyt is -. This morning NCYT shares opened at - |
Posted at 25/10/2024 06:57 by levinson1 I did not hear it. My view though is that NCYT constantly working with big companies and they are worth 3x current share price as real nav. Big Boys'Sliderules are most likely assessing this |
Posted at 21/10/2024 10:38 by strawberry alarm clock Everything is always good news in the sad little levinson1 world ... but the share price continues to fall What a sad pathetic little man |
Posted at 17/10/2024 19:51 by levinson1 Today's RNSThis is the sort of news which should assist in us growing organically. In England, Scotland, Wales & Ni, all babies are screened at birth for CF.If this is one of few approved tests it should enhance our ability to be able to sell into the NHS.No idea in Europe & beyond if CF testing is mandatory. Good news and hopefully selected CS because they have a plan to monetise it.IMO share price will catch up fast soon |
Posted at 04/10/2024 08:05 by levinson1 Already up 6.25% today. Very exciting share. Upside could be limited to £1.20 ish per share as bidders imo must be looking to buy. It's market cap at this ridiculously share price is probably under half the CO's real value |
Posted at 30/9/2024 15:34 by strawberry alarm clock Levinson1 quite today * Stable start. IMO big recovery to come soon*Share price then fell 8.5%What a tool BWAHAHAHA |
Posted at 15/9/2024 16:36 by dudishes Lev, the current short list of Friday does not list NCYT.The demise in the share price is purely down to what longs think it is worth buying. Go buy, improve the price? Shorts (SP) have absolutely nothing to do with the current price, from 120 to 69. I think they call it business, or lack of! |
Posted at 12/9/2024 15:43 by dudishes Just 3 shorts on the books at the moment, PAGE, BRBY and NCYT.NCYT by far the winner, 30%+ and counting. Have I got it wrong? Unaudited accounts to be re issued? Maybe an attempt for saving face, but not saving money as it costs. BTW, Yourgene, cost NCYT over £16M. |
Posted at 10/9/2024 13:55 by aimgamblerssupportgroup Are you slow on the uptake Baldrick?Please tell me where you expect the profit to come from, I am all ears. Yougene last full year results before NCYT Turnover £37.6 million loss £3.4 million (includes covid 19 sales) -------------------- NCYT 2024 30th May Turnover £11.5 million] Loss £28 million w/ex £17.8 million -------------------- As from the last NCYT results, on a pro-rata rate assuming the acquisition of Yougene was a full trading year 2023 reulsts are thus. Revenue £22.8 million full-year loss of 50 million. So the group went form a proforma £47 mill revenue to £22.8 in 2023. and a loss of £31 million to £50 million. Horrid! |
Posted at 05/9/2024 16:40 by levinson1 More buys than sales today yet price marked down. Could this be market makers building inventory. AI says : Your suggestion touches on an interesting and somewhat controversial aspect of market making. You're correct that this could potentially be a motivation for market makers . Let's explore this idea:1. Building inventory: Market makers might indeed lower prices to encourage selling, allowing them to build up their inventory of shares at a lower cost.2. Anticipating price rises: If they have reason to believe the share price will increase soon, accumulating shares at a lower price could position them for future profits.3 Profit motivation: As for-profit entities, market makers have an incentive to maximize their gains, which could include strategies like the one you've described. While your hypothesis is plausible and such practices have been alleged in some cases, it's important to approach this idea cautiously. Market dynamics are complex, and what might look like manipulation could have other explanations.Would you like to discuss the ethical implications of such practices, or explore how regulators try to prevent market manipulation???????? |
Posted at 31/8/2024 05:58 by scarletbloomers Nyct Front and CentreMark my words they will be testing is what they do , it’s what they are known for. If Monkey pox disappears naturally then fair enough the share price will languish before slowly dropping back to a lower level bearing in mind with the tax rebate it won’t drop to low. But Monkey pox isn’t disappearing. The who are worried very worried if and when it spreads to the western world it will be reported and heavily reported . People are dying with m pox everyday in Africa they must be the numbers say so. Unfortunately the western media don’t care about what is happening in Africa. But as the African migration across Europe and the rest of the world continues Monkeypox will migrate with the migrants fact . If who don’t get on top of the spread quickly the will be to late . Many in the west won’t take a vaccine after all the misinformation we were given about Covid and the negative effects on many people the Covid vaccine had on them . I personally believe when you weigh up all the odds our money is well placed here. I bought NCYT at 34p last til around and sold a few at £11 most at £8 odd and the balance at £3.40 this share can be very volatile it moves very quickly in both directions. But if like me you believe we might have a problem with Monkey pox and migration then hold NCYT will be front and centre mark my words. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
